Proven Results - Premenopausal

KISQALI® (ribociclib) + HORMONE THERAPY

MBC CAN'T BE CURED. BUT IT CAN BE TREATED.

Live longer
without disease progression

KISQALI® (ribociclib) tablets is the first and only medication of its kind indicated specifically for younger (premenopausal) women with HR+, HER2- metastatic breast cancer. KISQALI along with hormone therapy (eg, letrozole or anastrozole) or fulvestrant has helped a wide range of women live longer without disease progression.

Proven Results with KISQALI for Premenopausal Metastatic Breast Cancer

The Face of Metastatic Breast Cancer

Watch the KISQALI® (ribociclib) video to meet a young woman representing the experience of living with HR+, HER2- metastatic breast cancer. Listen as she discusses the importance of advocating for yourself—and learn about proven treatment results seen with KISQALI.

TV Spot - Coming Soon v2